US2016193315A1PendingUtilityA1

Peptides shared among lethal cancers and therapeutic compositions comprising said peptides

44
Assignee: BOGOCH SAMUELPriority: Aug 7, 2009Filed: Mar 17, 2016Published: Jul 7, 2016
Est. expiryAug 7, 2029(~3 yrs left)· nominal 20-yr term from priority
Inventors:Samuel BogochElenore S. BogochAnne Elenore Borsanyi
A61P 35/00C07K 7/08C07K 14/4748C07K 7/06C07K 16/30A61K 39/0011
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides cancer peptides related to rapid replication and shared among different histological cancer types. The peptides are provided in compositions for interfering with replication in cancer, in preventive and therapeutic vaccines, and in diagnostic applications. The compositions for interfering with replication in cancer are useful for preventing and treating different histological types of cancer including ectodermic, endodermic, and mesodermic cancers as well as cancers arising in association with HIV.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition for interfering with replication of cancer comprising at least one sequence of SEQ ID NO(s): 1-203. 
     
     
         2 . The composition of  claim 1  comprising at least one peptide consisting essentially of at least one of SEQ ID NO(s): 1-203. 
     
     
         3 . The composition of  claim 1  comprising a mixture of at least two peptides of SEQ ID NO(s): 1-27, SEQ ID NO(s): 28-52, SEQ ID NO(s): 53-103, SEQ ID NO(s): 104-148, SEQ ID NO(s): 149-165, and SEQ ID NO(s): 166-203. 
     
     
         4 . The composition of  claim 1  comprising a protein comprising at least one sequence of SEQ ID NO(s): 1-203. 
     
     
         5 . The composition of  claim 1 , wherein said composition is for direct or indirect interference with replication of cancer. 
     
     
         6 . The composition of  claim 5 , wherein said composition is for indirect interference with cancer where the indirect interference is mediated by an immune response. 
     
     
         7 . An isolated or synthesized protein fragment or peptide comprising at least one of SEQ ID NO(s): 1-203 or a sequence sharing at least 70% identity with at least one of SEQ ID NO(s): 1-203. 
     
     
         8 . The isolated or synthesized protein fragment or peptide of  claim 7  consisting essentially of a peptide of at least one of SEQ ID NO(s): 1-203. 
     
     
         9 . The isolated or synthesized protein fragment or peptide of  claim 7  consisting of at least one of SEQ ID NO(s): 1-203. 
     
     
         10 . A vaccine comprising at least one of SEQ ID NO(s): 1-27, SEQ ID NO(s): 28-52, SEQ ID NO(s): 53-103, SEQ ID NO(s): 104-148, SEQ ID NO(s): 149-165, and SEQ ID NO(s): 166-203 or a sequence sharing at least 70% identity with at least one of SEQ ID NO(s): 1-27, SEQ ID NO(s): 28-52, SEQ ID NO(s): 53-103, SEQ ID NO(s): 104-148, SEQ ID NO(s): 149-165, and SEQ ID NO(s): 166-203. 
     
     
         11 . A vaccine of  claim 10  comprising a mixture of at least two of a sequence of SEQ ID NO(s): 1-203 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 1-203. 
     
     
         12 . A vaccine of  claim 10  directed against cancer in a patient suffering from HIV comprising at least one sequence of SEQ ID NO(s): 104-148 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 104-148. 
     
     
         13 . A vaccine of  claim 10  directed against one or more of glioblastoma multiforme, pancreatic cancer, lung cancer, leukemia, colon cancer, colorectal cancer, cervical cancer, and breast cancer. 
     
     
         14 . A vaccine of  claim 13  directed at least against glioblastoma multiforme cancer comprising a sequence of SEQ ID NO(s): 1-27 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 1-27. 
     
     
         15 . A vaccine of  claim 13  directed at least against pancreatic cancer comprising a sequence of SEQ ID NO(s): 28-52 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 28-52. 
     
     
         16 . A vaccine of  claim 13  directed at least against lung cancer comprising a sequence of SEQ ID NO(s): 53-103 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 53-103. 
     
     
         17 . A vaccine of  claim 13  directed at least against leukemia comprising a sequence of SEQ ID NO(s): 149-165 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 149-165. 
     
     
         18 . A vaccine of  claim 13  directed at least against colon cancer, colorectal cancer, or cervical cancer comprising a sequence of SEQ ID NO(s): 166-193 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 166-193. 
     
     
         19 . A vaccine of  claim 13  directed at least against breast cancer comprising a sequence of SEQ ID NO(s): 194-203 or a sequence sharing at least 70% identity with a sequence of SEQ ID NO(s): 194-203. 
     
     
         20 . A vaccine of  claim 10  comprising at least one protein comprising at least one of SEQ ID NO(s): 1-203 or at least one protein fragment comprising at least one of SEQ ID NO(s): 1-203. 
     
     
         21 . An isolated, chemically-synthesized, or recombinantly-generated binding molecule that specifically binds at least one sequence of SEQ ID NO(s): 1-203. 
     
     
         22 . The isolated, chemically-synthesized, or recombinantly-generated binding molecule of  claim 21  that is an antibody or antibody fragment.

Join the waitlist — get patent alerts

Track US2016193315A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.